RDUS - Radius Recycling Inc. Debt to Book Capitalization Ratio

Graphic logo of Radius Recycling Inc. (RDUS)

Metal recycling operations provide Radius Recycling, Inc. (RDUS) with sustainable working capital. The debt-to-capitalization ratio reflects current dynamics, where the parameter value equals 1.13. Its status as a key scrap aggregator guarantees stable demand, while developments in molecular biology and synthesis establish a robust scientific foundation for the company's future growth.

RDUS (Radius Pharmaceuticals) Debt to Book Value history from 07/04/2022 to 07/26/2025
Core merchandise of Radius Health

When assessing the resilience of Radius Recycling, Inc. (RDUS), I focus on the capital structure. This ratio compares total borrowings to the company's book value, measuring the degree of financial autonomy. By analyzing the dynamic debt-to-book capitalization metric, an investor determines the risk of credit pressure. For Radius Recycling, Inc. (RDUS), a low debt load confirms operational reliability, which reinforces B2B partner confidence in a stable metal recycling operator.

Competitors of Radius Recycling, Inc. (RDUS)

Debts to Book Capitalization ASND (Ascendis Pharma A/S)|madrigalpharma.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Corcept Therapeutics Incorporated (CORT)|RYTM: Debt to Net Assets Ratio|AKRO (Akero Therapeutics Inc) - Debt to Book Capitalization Ratio|Metsera Therapeutics (MTSR) - Debt to Book Value|MLTX (MoonLake Immunotherapeutics) - Debts to Book Capitalization|Debts to Book Capitalization crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Debt to Book Value|Debt to Net Assets Ratio SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Debt to Book Capitalization Ratio|Debt to Book Value 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Debts to Book Capitalization|structuretx.com (GPCR) - Debts to Book Value|MDXG - Debt to Book Value|Rezolute Inc (RZLT) - Debt to Book Capital|LXRX (Lexicon Pharma) - Debts to Book Capitalization|Debts to Book Capitalization MBX Corp|Debts to Book Capitalization Altimmune, Inc. (ALT)|Debt to Book Capitalization Ratio AARD (aardvarktherapeutics.com)|SGMT: Debt to Book Capitalization Ratio|BioAge Labs - Debts to Book Value|BMEA - Debt to Book Capitalization Ratio|QNCX - Debt to Book Capitalization Ratio|Fractyl Health, Inc. - Debts to Book Capitalization|VTVT (vTv Therapeutics) - Debts to Net Assets|ATPC: Debt to Book Capitalization Ratio|Debts to Net Assets PLUR|Debt to Book Capitalization Ratio SYBX (Synlogic, Inc.)|Debt to Book Value LPCN (Lipocine Corporation)|Debt to Book Capitalization Ratio Matinas BioPharma Holdings|Debt to Net Assets Ratio Spruce Biosciences Inc. SPRB|Galecto - Debts to Book Capitalization|CTCX - Debts to Book Capitalization|Debts to Book Capitalization Lumos Pharma Corp|Organovo Corp (ONVO) - Debt to Book Value Ratio